Base de dados : MEDLINE
Pesquisa : D27.505.519.186.071 [Categoria DeCS]
Referências encontradas : 13859 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1386 ir para página                         

  1 / 13859 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29303009
[Au] Autor:Katsiki N; Kolovou G; Perez-Martinez P; Mikhailidis DP
[Ad] Endereço:a Second Propedeutic Department of Internal Medicine, Medical School , Aristotle University of Thessaloniki, Hippocration Hospital , Thessaloniki , Greece.
[Ti] Título:Dyslipidaemia in the elderly: to treat or not to treat?
[So] Source:Expert Rev Clin Pharmacol;11(3):259-278, 2018 Mar.
[Is] ISSN:1751-2441
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The elderly population (i.e. aged ≥ 65 years) is increasing worldwide. Ageing is associated with a higher incidence and prevalence of cardiovascular disease (CVD). Areas covered: The prevalence of CVD risk factors including type 2 diabetes mellitus, hypertension and dyslipidaemia also increases with advancing age, contributing to the higher absolute CVD risk observed in the elderly. The present narrative review comments on the associations of dyslipidaemia with CVD as well as the effects of lifestyle measures and lipid-lowering drugs on lipids and CVD risk with a special focus on the elderly population. Individual treatment goals and therapeutic options according to current guidelines are also reviewed. Finally, we discuss special characteristics of the elderly that may influence the efficacy and safety of drug therapy and should be considered before selection of hypolipidaemic pharmacotherapy. Expert commentary: There may be a greater CVD benefit in older patients following drug therapy compared with younger ones. Treatment goals and therapeutic options should be individualized according to current guidelines. Specific characteristics that may influence the efficacy and safety of drug therapy in the elderly should be considered in relation to dyslipidaemia treatment.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Dislipidemias/tratamento farmacológico
Hipolipemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Fatores Etários
Idoso
Doenças Cardiovasculares/etiologia
Dislipidemias/complicações
Dislipidemias/epidemiologia
Seres Humanos
Hipolipemiantes/efeitos adversos
Incidência
Estilo de Vida
Guias de Prática Clínica como Assunto
Prevalência
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypolipidemic Agents)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180106
[St] Status:MEDLINE
[do] DOI:10.1080/17512433.2018.1425138


  2 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29352300
[Au] Autor:Wang Z; Koonen D; Hofker M; Bao Z
[Ad] Endereço:Department of Geriatrics and Gastroenterology, Huadong Hospital, Shanghai Medical College, Fudan University, Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, P.R. China.
[Ti] Título:5-aminosalicylic acid improves lipid profile in mice fed a high-fat cholesterol diet through its dual effects on intestinal PPARγ and PPARα.
[So] Source:PLoS One;13(1):e0191485, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Obesity is associated with a series of metabolic complications, including dyslipidemia and insulin resistance (IR) that lack effective therapies. In recent years, intestinal inflammation has been suggested to contribute to obesity related metabolic syndrome and targeting gut inflammation with 5-ASA improves diet induced IR, however, its role in dyslipidemia is unknown and has never been explored. In the present study, we reported for the first time that administration of 5-ASA for 12 weeks significantly improved lipid profile by repressing plasma triglycerides and free cholesterol levels in mice fed high-fat cholesterol diet (HFC). In addition, liver lipids were significantly reduced by 5-ASA treatment in HFC-fed mice. Mechanistically, anti-inflammatory genes peroxisome proliferator-activated receptor-γ (Pparγ) and M2 marker, such as Mrc1 and Ym1, were remarkably upregulated, while pro-inflammation gene monocyte chemoattractant protein-1 (Mcp-1) were downregulated in small intestine of mice treated by 5-ASA. Further, 5-ASA improved gastrointestinal barrier by increasing the expression of the tight junction marker ZO-1. 5-ASA also enhanced cholesterol translocation by elevating genes expression of Npc1l1 and Abcg5/8. Moreover, mice fed HFC 5-ASA expressed increased Pparα in small intestinal and its target genes function in lipid oxidation and hydrolysis were remarkable elevated. Taken together, we reported a novel role of 5-ASA which may serve as a therapy target intestinal inflammation induced dyslipidemia.
[Mh] Termos MeSH primário: Colesterol na Dieta/administração & dosagem
Dieta Hiperlipídica/efeitos adversos
Intestinos/efeitos dos fármacos
Intestinos/metabolismo
Metabolismo dos Lipídeos/efeitos dos fármacos
Mesalamina/farmacologia
PPAR alfa/metabolismo
PPAR gama/metabolismo
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/farmacologia
Dislipidemias/tratamento farmacológico
Dislipidemias/genética
Dislipidemias/metabolismo
Ácidos Graxos/metabolismo
Hipolipemiantes/farmacologia
Inflamação/tratamento farmacológico
Inflamação/genética
Inflamação/metabolismo
Metabolismo dos Lipídeos/genética
Lipídeos/sangue
Fígado/efeitos dos fármacos
Fígado/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
PPAR gama/genética
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Cholesterol, Dietary); 0 (Fatty Acids); 0 (Hypolipidemic Agents); 0 (Lipids); 0 (PPAR alpha); 0 (PPAR gamma); 0 (RNA, Messenger); 4Q81I59GXC (Mesalamine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180121
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0191485


  3 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254319
[Au] Autor:Musolino V; Gliozzi M; Carresi C; Maiuolo J; Mollace R; Bosco F; Scarano F; Scicchitano M; Maretta A; Palma E; Iannone M; Morittu VM; Gratteri S; Muscoli C; Fini M; Mollace V
[Ad] Endereço:Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Science, Magna Græcia University of Catanzaro, Catanzaro, Italy.
[Ti] Título:Lipid-lowering effect of bergamot polyphenolic fraction: role of pancreatic cholesterol ester hydrolase.
[So] Source:J Biol Regul Homeost Agents;31(4):1087-1093, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Bergamot polyphenolic fraction (BPF) has been shown to positively modulate several mechanisms involved in metabolic syndrome, suggesting its use in therapy. In particular, it is able to induce a significant amelioration of serum lipid profile in hyperlipemic patients at different levels. The purpose of our study was to investigate the effect of BPF on cholesterol absorption physiologically mediated by pancreatic cholesterol ester hydrolase (pCEH). An in vitro activity assay was performed to study the effect of BPF on pCEH, whereas the rate of cholesterol absorption was evaluated through in vivo studies. In particular, male, Sprague-Dawley rats (200–225 g) were fed either normal chow or chow supplemented with 0.5% cholic acid, 5.5% peanut oil, and varying amounts of cholesterol (0 to 1.5%). BPF (10 mg/Kg) was daily administrated by means of a gastric gavage to animals fed with lipid supplemented diet for 4 weeks and, at the end of the study, plasma lipids and liver cholesteryl esters were measured in all experimental groups. Our results show that BPF was able to inhibit pCEH activity and this effect was confirmed, in vivo, via detection of lymphatic cholesteryl ester in rats fed with a cholesterol-rich diet. This evidence clarifies a further mechanism responsible for the hypolipemic properties of BPF previously observed in humans, confirming its beneficial effect in the therapy of hypercholesterolemia and in the treatment of metabolic syndrome.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/farmacologia
Óleos Vegetais/farmacologia
Esterol Esterase/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Colesterol/administração & dosagem
Colesterol/sangue
Ésteres do Colesterol/sangue
Ácido Cólico/administração & dosagem
Ácido Cólico/sangue
Absorção Gastrointestinal/fisiologia
Seres Humanos
Hiperlipidemias/metabolismo
Hiperlipidemias/patologia
Hipolipemiantes/metabolismo
Fígado/efeitos dos fármacos
Fígado/metabolismo
Masculino
Síndrome Metabólica/tratamento farmacológico
Síndrome Metabólica/metabolismo
Síndrome Metabólica/patologia
Óleos Vegetais/metabolismo
Ratos
Ratos Sprague-Dawley
Esterol Esterase/metabolismo
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol Esters); 0 (Hypolipidemic Agents); 0 (Plant Oils); 0 (Triglycerides); 39W1PKE3JI (bergamot oil); 97C5T2UQ7J (Cholesterol); EC 3.1.1.- (bile salt-stimulated lipase); EC 3.1.1.13 (Sterol Esterase); G1JO7801AE (Cholic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  4 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464894
[Au] Autor:Zhao MJ; Wang SS; Jiang Y; Wang Y; Shen H; Xu P; Xiang H; Xiao H
[Ad] Endereço:Nanjing Medical University, Affiliated Nanjing Brain Hospital, No. 264 Guangzhou Road, Nanjing, Jiangsu, 210029, People's Republic of China.
[Ti] Título:Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism.
[So] Source:Lipids Health Dis;16(1):85, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The novel compound XH601 is a synthesized derivative of formononetin. The present study was to investigate the hypolipidemia effect and potential mechanism of XH601. METHODS: Male Golden Syrian hamsters were induced by high-fat diet (HFD) for eight weeks and the hyperlipidemic model was established successfully. After XH601 treatment, serum and hepatic biochemistry parameters of hamsters were detected and the effect of XH601 on adipose tissue was also analyzed. Furthermore, 3 T3-L1 cell differentiation by Oil-Red-O staining was observed and the mRNA and protein expression of peroxisome proliferator-activated receptors (PPARs) were measured by qRT-PCR and Western-blot in mature adipocytes. RESULTS: The in vivo results suggest that XH601 significantly decreased the adipose weight and levels of serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), apolipoprotein B (Apo-B), apolipoprotein E (Apo-E), while increased serum high-density lipoprotein (HDL-C). The in vitro results implied that XH601 up-regulated the mRNA and protein expression of both PPARα and PPARß/δ in a dose-dependent manner. CONCLUSIONS: The study suggests that XH601 exhibited strong ability to improve the dyslipidemia in hamsters fed with high-fat diet. The potential mechanism of XH601 was associated with the up-regulation of PPARα and PPARß/δ mRNA and protein expression.
[Mh] Termos MeSH primário: Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/farmacologia
Isoflavonas/farmacologia
PPAR alfa/agonistas
PPAR delta/agonistas
PPAR beta/agonistas
[Mh] Termos MeSH secundário: Células 3T3-L1
Tecido Adiposo/efeitos dos fármacos
Tecido Adiposo/metabolismo
Tecido Adiposo/patologia
Animais
Apolipoproteínas B/sangue
Apolipoproteínas E/sangue
Diferenciação Celular
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Cricetinae
Dieta Hiperlipídica/efeitos adversos
Regulação da Expressão Gênica
Hiperlipidemias/etiologia
Hiperlipidemias/metabolismo
Hiperlipidemias/patologia
Masculino
Mesocricetus
Camundongos
PPAR alfa/genética
PPAR alfa/metabolismo
PPAR delta/genética
PPAR delta/metabolismo
PPAR beta/genética
PPAR beta/metabolismo
RNA Mensageiro/agonistas
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Apolipoproteins B); 0 (Apolipoproteins E); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hypolipidemic Agents); 0 (Isoflavones); 0 (PPAR alpha); 0 (PPAR delta); 0 (PPAR-beta); 0 (RNA, Messenger); 0 (Triglycerides); 295DQC67BJ (formononetin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0472-z


  5 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29247651
[Au] Autor:Zhou F; Bai M; Zhang Y; Zhu Q; Zhang L; Zhang Q; Wang S; Zhu K; Liu Y; Wang X; Zhou L
[Ad] Endereço:Shanghai Institute of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
[Ti] Título:Berberine-induced activation of AMPK increases hepatic FGF21 expression via NUR77.
[So] Source:Biochem Biophys Res Commun;495(2):1936-1941, 2018 01 08.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Fibroblast growth factor 21 (FGF21), a hormone-like protein mainly derived from liver, exhibits multiple beneficial effect on energy metabolism. Similar to FGF21, berberine exerts anti-hyperglycemic and anti-dyslipidemic properties. Previous studies revealed that the beneficial metabolic effect of berberine was attributed to the activation of AMP-activated protein kinase (AMPK). Here we investigated the effect of berberine on FGF21 expression in primary mouse hepatocytes. As expected, berberine induced hepatic FGF21 expression in a dose-dependent and time-dependent manner, along with the increased expression of NUR77, a proved transcription factor of FGF21. Berberine stimulated the phosphorylations of AMPK and acetyl-CoA carboxylase in primary mouse hepatocytes. Adenovirus-mediated overexpression of constitutively active AMPK triggered hepatic FGF21 and NUR77 expressions. The inhibition of AMPK by compound C abolished berberine-stimulated FGF21 and NUR77 expressions. These results suggest that berberine-induced activation of AMPK may contribute to hepatic FGF21 expression via NUR77.
[Mh] Termos MeSH primário: Berberina/administração & dosagem
Fatores de Crescimento de Fibroblastos/metabolismo
Hepatócitos/metabolismo
Membro 1 do Grupo A da Subfamília 4 de Receptores Nucleares/metabolismo
Proteínas Quinases/metabolismo
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Relação Dose-Resposta a Droga
Ativação Enzimática/efeitos dos fármacos
Ativação Enzimática/fisiologia
Hepatócitos/efeitos dos fármacos
Hipoglicemiantes/administração & dosagem
Hipolipemiantes/administração & dosagem
Masculino
Redes e Vias Metabólicas/efeitos dos fármacos
Redes e Vias Metabólicas/fisiologia
Camundongos
Camundongos Endogâmicos C57BL
Regulação para Cima/efeitos dos fármacos
Regulação para Cima/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Hypoglycemic Agents); 0 (Hypolipidemic Agents); 0 (Nr4a1 protein, mouse); 0 (Nuclear Receptor Subfamily 4, Group A, Member 1); 0 (fibroblast growth factor 21); 0I8Y3P32UF (Berberine); 62031-54-3 (Fibroblast Growth Factors); EC 2.7.- (Protein Kinases); EC 2.7.1.- (AMP-activated protein kinase kinase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE


  6 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390422
[Au] Autor:Marginean CO; Melit LE; Dobreanu M; Marginean MO
[Ad] Endereço:Department of Pediatrics I, University of Medicine and Pharmacy Tirgu Mures, Romania.
[Ti] Título:Type V hypertriglyceridemia in children, a therapeutic challenge in pediatrics: A case report and a review of the literature.
[So] Source:Medicine (Baltimore);96(51):e8864, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Hypertriglyceridemia is defined as a level of triglycerides above 150 mg/dL. The complex causes and classification of hypertriglyceridemia lead to difficulties in the diagnosis and management of this condition. PATIENT CONCERNS: We present the case of a 15 years and 6 months old female teenager, admitted in our clinic for the following complaints: severe abdominal pain predominantly in the lateral left quadrant, nausea, vomiting, and the lack of stools for 2 days. The clinical exam showed: impaired general status, painful abdomen at superficial and deep palpation in the left and upper abdominal quadrants, the absence of stools for 2 days. DIAGNOSES: The laboratory parameters revealed leukocytosis with neutrophilia, thrombocytopenia, high level of serum amylase and triglycerides, and increased inflammatory biomarkers. The imagistic investigations showed ascites and paralytic ileus. INTERVENTIONS: The management was burdened by the side-effects of hypolipidemic drugs impairing the liver function and leading to rhabdomyolysis, but eventually the patient's outcome was good. OUTCOMES: Type V hyperlipoproteinemia is a rare condition accounting for approximately 5% of the cases. The risk for acute pancreatitis is well-known to be associated with hypertriglyceridemia, even though in rare cases. LESSONS: The prognosis of hypertriglyceridemia is pediatrics is burdened not only by the long-term risk factors associated to the diseases itself, but also by the negative effects of long-term hypolipidemic treatment.
[Mh] Termos MeSH primário: Hipertrigliceridemia/diagnóstico
Hipolipemiantes/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Diagnóstico Diferencial
Feminino
Seres Humanos
Hipertrigliceridemia/sangue
Hipertrigliceridemia/complicações
Hipolipemiantes/administração & dosagem
Hipolipemiantes/efeitos adversos
Rabdomiólise/induzido quimicamente
Rabdomiólise/complicações
Triglicerídeos/sangue
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Triglycerides)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008864


  7 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29305303
[Au] Autor:Lu J; Cheng B; Meng Z; Fang B; Li T; Sun M; Liu M; Guan S
[Ad] Endereço:Food Science and Engineering College, Jilin University, Changchun, Jilin Province 130062, PR China.
[Ti] Título:Alliin attenuates 1, 3-dichloro-2-propanol-induced lipogenesis in HepG2 cells through activation of the AMP-activated protein kinase-dependent pathway.
[So] Source:Life Sci;195:19-24, 2018 Feb 15.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Accumulating evidence reveals the association of 1, 3-dichloro-2-propanol (1, 3-DCP) exposure and lipogenesis. Alliin, the most abundant sulphur compound in garlic, has been demonstrated to exhibit hypoglycemic, antioxidant and anti-inflammatory activities. Here, we showed that alliin attenuated lipogenesis induced by 1,3-DCP and that the reduction was due to activation of the AMPK pathway. HepG2 cells exposed to 1,3-DCP exhibited significant increase of triglyceride(TG) and total cholesterol(TC), and alliin reduced the accumulation. Most importantly, alliin could up-regulate the phosphorylation of AMPK and down-regulate protein and gene expressions of SREBP-1; FAS; SREBP-2;HMGCR in 1,3-DCP-induced HepG2 cells. The results demonstrated that alliin was effective on attenuating 1,3-DCP-induced lipogenesis via activation of the AMPK-SREBPs signaling pathway in HepG2 cells.
[Mh] Termos MeSH primário: Proteínas Quinases Ativadas por AMP/metabolismo
Cisteína/análogos & derivados
Hipolipemiantes/farmacologia
Metabolismo dos Lipídeos/efeitos dos fármacos
Transdução de Sinais/efeitos dos fármacos
alfa-Cloridrina/análogos & derivados
[Mh] Termos MeSH secundário: Sobrevivência Celular/efeitos dos fármacos
Colesterol/biossíntese
Cisteína/farmacologia
Ativação Enzimática/efeitos dos fármacos
Regulação da Expressão Gênica/efeitos dos fármacos
Células Hep G2
Seres Humanos
Proteínas de Ligação a Elemento Regulador de Esterol/biossíntese
Proteínas de Ligação a Elemento Regulador de Esterol/genética
Triglicerídeos/biossíntese
alfa-Cloridrina/antagonistas & inibidores
alfa-Cloridrina/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Sterol Regulatory Element Binding Proteins); 0 (Triglycerides); 0F4P2VQC07 (1,3-dichloro-2-propanol); 7I4L2D0E9G (alliin); 96-24-2 (alpha-Chlorohydrin); 97C5T2UQ7J (Cholesterol); EC 2.7.11.31 (AMP-Activated Protein Kinases); K848JZ4886 (Cysteine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180107
[St] Status:MEDLINE


  8 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241894
[Au] Autor:Adams AS; Madden JM; Zhang F; Lu CY; Ross-Degnan D; Lee A; Soumerai SB; Gilden D; Chawla N; Griggs JJ
[Ad] Endereço:Kaiser Permanente Division of Research, Oakland, CA, USA. Electronic address: Alyce.S.Adams@kp.org.
[Ti] Título:Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.
[So] Source:Value Health;20(10):1345-1354, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To evaluate the impact of transitioning from Medicaid to Medicare Part D drug coverage on the use of noncancer treatments among dual enrollees with cancer. METHODS: We leveraged a representative 5% national sample of all fee-for-service dual enrollees in the United States (2004-2007) to evaluate the impact of the removal of caps on the number of reimbursable prescriptions per month (drug caps) under Part D on 1) prevalence and 2) average days' supply dispensed for antidepressants, antihypertensives, and lipid-lowering agents overall and by race (white and black). RESULTS: The removal of drug caps was associated with increased use of lipid-lowering medications (days' supply 3.63; 95% confidence interval [CI] 1.57-5.70). Among blacks in capped states, we observed increased use of lipid-lowering therapy (any use 0.08 percentage points; 95% CI 0.05-0.10; and days' supply 4.01; 95% CI 2.92-5.09) and antidepressants (days' supply 2.20; 95% CI 0.61-3.78) and increasing trends in antihypertensive use (any use 0.01 percentage points; 95% CI 0.004-0.01; and days' supply 1.83; 95% CI 1.25-2.41). The white-black gap in the use of lipid-lowering medications was immediately reduced (-0.09 percentage points; 95% CI -0.15 to -0.04). We also observed a reversal in trends toward widening white-black differences in antihypertensive use (level -0.08 percentage points; 95% CI -0.12 to -0.05; and trend -0.01 percentage points; 95% CI -0.02 to -0.01) and antidepressant use (-0.004 percentage points; 95% CI -0.01 to -0.0004). CONCLUSIONS: Our findings suggest that the removal of drug caps under Part D had a modest impact on the treatment of hypercholesterolemia overall and may have reduced white-black gaps in the use of lipid-lowering and antidepressant therapies.
[Mh] Termos MeSH primário: Antidepressivos/administração & dosagem
Anti-Hipertensivos/administração & dosagem
Hipolipemiantes/administração & dosagem
Medicare Part D/economia
Neoplasias/tratamento farmacológico
[Mh] Termos MeSH secundário: Afroamericanos/estatística & dados numéricos
Idoso
Antidepressivos/economia
Anti-Hipertensivos/economia
Grupo com Ancestrais do Continente Europeu/estatística & dados numéricos
Planos de Pagamento por Serviço Prestado
Feminino
Acesso aos Serviços de Saúde
Seres Humanos
Hipercolesterolemia/tratamento farmacológico
Hipercolesterolemia/economia
Hipolipemiantes/economia
Masculino
Medicaid/economia
Meia-Idade
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Antidepressive Agents); 0 (Antihypertensive Agents); 0 (Hypolipidemic Agents)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE


  9 / 13859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29273563
[Au] Autor:Olas B; Brys M
[Ad] Endereço:Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland. Electronic address: beata.olas@biol.uni.lodz.pl.
[Ti] Título:Is it safe to use Acorus calamus as a source of promising bioactive compounds in prevention and treatment of cardiovascular diseases?
[So] Source:Chem Biol Interact;281:32-36, 2018 Feb 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Acorus calamus has a rich history in natural medicine, and offers many health benefits. The plant has anti-inflammatory, antimicrobial, diuretic, antiurolithiatic and other properties. Moreover, various parts, especially the rhizome and roots, are sources of a range of bioactive phenolic compounds with beneficial effects on the cardiovascular system. This review article summarizes the current knowledge of the chemical composition of different parts of A. calamus and their roles in the prevention and treatment of cardiovascular diseases. However, as no human studies have been performed, the review only includes in vitro and animal studies. The paper also briefly reviews the toxicity of A. calamus and its products for human health, especially regarding the cardiovascular system.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/prevenção & controle
Óleos Voláteis/uso terapêutico
[Mh] Termos MeSH secundário: Acorus/química
Acorus/metabolismo
Animais
Anisóis/química
Anisóis/metabolismo
Anisóis/uso terapêutico
Peso Corporal/efeitos dos fármacos
Doenças Cardiovasculares/tratamento farmacológico
Compostos de Epóxi/química
Compostos de Epóxi/metabolismo
Compostos de Epóxi/toxicidade
Seres Humanos
Hipolipemiantes/química
Hipolipemiantes/uso terapêutico
Óleos Voláteis/química
Óleos Voláteis/metabolismo
Fenóis/química
Fenóis/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anisoles); 0 (Epoxy Compounds); 0 (Hypolipidemic Agents); 0 (Oils, Volatile); 0 (Phenols); 0 (asarone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171224
[St] Status:MEDLINE


  10 / 13859 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29232626
[Au] Autor:Wen C; Wang D; Li X; Huang T; Huang C; Hu K
[Ad] Endereço:State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China; University of Chinese Academy of Sciences, Beijing 100049, China.
[Ti] Título:Targeted isolation and identification of bioactive compounds lowering cholesterol in the crude extracts of crabapples using UPLC-DAD-MS-SPE/NMR based on pharmacology-guided PLS-DA.
[So] Source:J Pharm Biomed Anal;150:144-151, 2018 Feb 20.
[Is] ISSN:1873-264X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The anti-hyperlipidemic effects of crude crabapple extracts derived from Malus 'Red jade', Malus hupehensis (Pamp.) Rehd. and Malus prunifolia (Willd.) Borkh. were evaluated on high-fat diet induced obese (HF DIO) mice. The results revealed that some of these extracts could lower serum cholesterol levels in HF DIO mice. The same extracts were also parallelly analyzed by LC-MS in both positive and negative ionization modes. Based on the pharmacological results, 22 LC-MS variables were identified to be correlated with the anti-hyperlipidemic effects using partial least square discriminant analysis (PLS-DA) and independent samples t-test. Further, under the guidance of the bioactivity-correlated LC-MS signals, 10 compounds were targetedly isolated and enriched using UPLC-DAD-MS-SPE and identified/elucidated by NMR together with MS/MS as citric acid(1), p-coumaric acid(2), hyperoside(3), myricetin(4), naringenin(5), quercetin(6), kaempferol(7), gentiopicroside(8), ursolic acid(9) and 8-epiloganic acid(10). Among these 10 compounds, 6 compounds, hyperoside(3), myricetin(4), naringenin(5), quercetin(6), kaempferol(7) and ursolic acid(9), were individually studied and reported to indeed have effects on lowering the serum lipid levels. These results demonstrated the efficiency of this strategy for drug discovery. In contrast to traditional routes to discover bioactive compounds in the plant extracts, targeted isolation and identification of bioactive compounds in the crude plant extracts using UPLC-DAD-MS-SPE/NMR based on pharmacology-guided PLS-DA of LC-MS data brings forward a new efficient dereplicated approach to natural products research for drug discovery.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Hipolipemiantes/isolamento & purificação
Malus/química
Extratos Vegetais/química
[Mh] Termos MeSH secundário: Animais
Colesterol/sangue
Cromatografia Líquida/métodos
Análise Discriminante
Feminino
Hipolipemiantes/análise
Hipolipemiantes/farmacologia
Análise dos Mínimos Quadrados
Espectroscopia de Ressonância Magnética
Espectrometria de Massas/métodos
Camundongos
Camundongos Endogâmicos C57BL
Obesidade/tratamento farmacológico
Extratos Vegetais/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hypolipidemic Agents); 0 (Plant Extracts); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180130
[Lr] Data última revisão:
180130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171213
[St] Status:MEDLINE



página 1 de 1386 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde